These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20035286)

  • 1. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
    Fujikawa T; Shiraha H; Yamamoto K
    Acta Med Okayama; 2009 Dec; 63(6):299-304. PubMed ID: 20035286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma.
    Cui SX; Yu XF; Qu XJ
    Cancer Invest; 2016 Oct; 34(9):459-464. PubMed ID: 27673353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma.
    Matsubara M; Shiraha H; Kataoka J; Iwamuro M; Horiguchi S; Nishina S; Takaoka N; Uemura M; Takaki A; Nakamura S; Kobayashi Y; Nouso K; Yamamoto K
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1602-8. PubMed ID: 22554292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
    Murata K; Sakamoto A
    Int J Oncol; 2008 Dec; 33(6):1149-55. PubMed ID: 19020747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Des-γ-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence.
    Gao J; Feng X; Inagaki Y; Song P; Kokudo N; Hasegawa K; Sugawara Y; Tang W
    Biosci Trends; 2012 Aug; 6(4):153-9. PubMed ID: 23006961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway.
    Yue P; Gao ZH; Xue X; Cui SX; Zhao CR; Yuan Y; Yin Z; Inagaki Y; Kokudo N; Tang W; Qu XJ
    Eur J Cancer; 2011 May; 47(7):1115-24. PubMed ID: 21349701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma.
    Taniguchi T; Kishi K; Nakagawa T; Tanaka H; Tanaka T; Tomonari T; Okamoto K; Sogabe M; Miyamoto H; Okahisa T; Muguruma N; Kajimoto M; Sagawa I; Takayama T
    Digestion; 2017; 95(3):242-251. PubMed ID: 28384634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin.
    Ma M; Qu XJ; Mu GY; Chen MH; Cheng YN; Kokudo N; Tang W; Cui SX
    Chemotherapy; 2009; 55(1):28-35. PubMed ID: 18974646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma.
    Sumi A; Akiba J; Ogasawara S; Nakayama M; Nomura Y; Yasumoto M; Sanada S; Nakashima O; Abe T; Yano H
    PLoS One; 2015; 10(3):e0118452. PubMed ID: 25739032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of vitamin K, immunoreactive prothrombin, des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity in hepatocellular carcinoma tissue.
    Yamagata H; Nakanishi T; Furukawa M; Okuda H; Obata H
    J Gastroenterol Hepatol; 1995; 10(1):8-13. PubMed ID: 7620113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma.
    Zhang YS; Chu JH; Cui SX; Song ZY; Qu XJ
    Cell Physiol Biochem; 2014; 34(3):903-15. PubMed ID: 25200250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.
    Cui SX; Zhang YS; Chu JH; Song ZY; Qu XJ
    Cell Physiol Biochem; 2015; 35(1):201-12. PubMed ID: 25591763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Des-gamma-carboxyprothrombin: clinical effectiveness and biochemical importance.
    Inagaki Y; Tang W; Xu H; Wang F; Nakata M; Sugawara Y; Kokudo N
    Biosci Trends; 2008 Apr; 2(2):53-60. PubMed ID: 20103901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
    Inagaki Y; Tang W; Makuuchi M; Hasegawa K; Sugawara Y; Kokudo N
    Liver Int; 2011 Jan; 31(1):22-35. PubMed ID: 20874725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
    Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
    Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.
    Suzuki M; Shiraha H; Fujikawa T; Takaoka N; Ueda N; Nakanishi Y; Koike K; Takaki A; Shiratori Y
    J Biol Chem; 2005 Feb; 280(8):6409-15. PubMed ID: 15582995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
    Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
    Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis.
    Inagaki Y; Xu HL; Hasegawa K; Aoki T; Beck Y; Sugawara Y; Tang W; Kokudo N
    J Dig Dis; 2011 Dec; 12(6):481-8. PubMed ID: 22118699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.